Latest Conference Articles
10 Years After HIV PrEP Approval, Uptake Lowest Among Highest Risk Groups
August 9th 2022, 8:30pm
Expanding Medicaid and reducing stigma can bolster equitable HIV PrEP access, Dr. Patrick Sullivan says.
Biktarvy Effective for HIV Patients Coinfected With Hepatitis B
August 1st 2022, 5:00pm
At AIDS 2022, Gilead presented data suggesting Biktarvy was a safe and effective complete HIV treatment regimen, including for those coinfected with hepatitis B.
Fostemsavir Improves Outcomes for Treatment-Resistant HIV Patients
July 30th 2022, 3:00pm
After 5 years of treatment, fostemsavir improved immunologic response and virologic outcome in patients with highly resistant HIV infection.
The Patient Impact of CDI, Preventing Reoccurrence
June 1st 2022, 12:00pm
A clinician discusses the disease burden of reoccurring CDI, but sees a silver lining in the new investigational therapies potentially changing the treatment paradigm for the better.
Rapid Diagnostic Testing’s Impact on Timing to Optimal Therapy
May 27th 2022, 1:59pm
Utilizing a newer technology, investigators wanted to see if a reduction in time led to clinically significant antimicrobial adjustments.
Measuring the Effectiveness of a Novel Antibiotic for Patients with Nontuberculous Mycobacterial Infections
May 27th 2022, 12:16pm
A multicenter study looked at treating these infections with omadacycline.
Monoclonal Antibody ADG20 Neutralizes COVID-19 Variants
May 26th 2022, 6:09pm
The investigational, fully human IgG1 monoclonal antibody ADG20 prevented and treated infection with COVID-19 variants of concern.
Investigating RBX2660 for Recurrent C Difficile Infection
May 24th 2022, 6:00pm
RBX2660, an investigational microbiota-based live biotherapeutic for the treatment of C difficile, safely and effectively reduced recurrent C diff for 6 months.